Contribution of viral mimics of cellular genes to KSHV infection and disease.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
rituximab 1 angiologydiseasesdrugs
Siltuximab 1 angiologydiseasesdrugs
primary effusion lymphoma 2 angiologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Siltuximab 7900 a proportion of the infected cells [[6],[27],[33],[34],[35]].There is no standard therapy for MCD. Siltuximab , a chimeric neutralizing monoclonal antibody against IL-6 has recently received FDA approval for use
rituximab 10466 and other typical B cell surface markers. Despite the absence of surface CD20, there is evidence that rituximab (anti-CD20 antibody) can be an effective treatment for some patients with PEL (Figure 1) [[41],[42]].
Select Disease Character Offset Disease Term Instance
primary effusion lymphoma 789 the cause of Kaposi sarcoma (KS), the most common malignancy in HIV-infected individuals worldwide, primary effusion lymphoma (PEL) and multicentric Castleman disease (MCD). KSHV is a double-stranded DNA virus that encodes several
primary effusion lymphoma 2006 herpesvirus that was shown to be the cause of Kaposi sarcoma (KS) [[1]]. Soon thereafter, HIV/AIDS-associated primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD) were linked to KSHV infection [[2],[3],[4],[5]].

You must be authorized to submit a review.